Supplementary Materials

Supplementary Material for:

In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy

Chao Wang, Jinqiang Wang, Xudong Zhang, Shuangjiang Yu, Di Wen, Quanyin Hu, Yanqi Ye, Hunter Bomba, Xiuli Hu, Zhuang Liu, Gianpietro Dotti, Zhen Gu*

*Corresponding author. Email: zgu{at}

Published 21 February 2018, Sci. Transl. Med. 10, eaan3682 (2018)
DOI: 10.1126/scitranslmed.aan3682

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Schematic of the H2O2 responsiveness mechanism of the PVA-TSPBA gel.
  • Fig. S2. Synthesis route and characterization of TSPBA.
  • Fig. S3. Dynamic rheological behavior of PVA before and after gelation.
  • Fig. S4. In vivo gel maintenance.
  • Fig. S5. Oxidation and hydrolysis of TSPBA.
  • Fig. S6. In vivo release of payloads from gel scaffold.
  • Fig. S7. Low-dose GEM@Gel for enhancement of lymphocyte infiltration.
  • Fig. S8. ROS-responsive scaffold as a scavenger of ROS within the TME.
  • Fig. S9. Frequency of CD4+FOXP3+ T cells within the tumors of mice receiving the indicated treatments.
  • Fig. S10. Effects of GEM on cancer cells in vitro.
  • Fig. S11. In vivo PD-L1 expression in tumor cells at different time points.
  • Fig. S12. Effects of GEM@Gel on systemic concentrations of cytokines.
  • Fig. S13. Tumor inhibition in mice treated with free drugs compared to aPDL1-GEM@Gel.
  • Fig. S14. Characterization of T cell–mediated antitumor immune response.
  • Fig. S15. PD-L1 expression in distant tumors.
  • Fig. S16. Effects of GEM on 4T1 cells in vitro.
  • Fig. S17. Biocompatibility of hydrogel in vivo.
  • Fig. S18. Body weight of control and treated mice.

[Download PDF]